Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Ipilimumab N01 + Bevacizumab in Unresectable Malignant Peritoneal Mesothelioma
NCT07893340Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Oct 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, ipilimumab, bevacizumab in peritoneal mesothelioma, sponsored by Fudan University. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
sintilimabipilimumabbevacizumab
03
Conditions
peritoneal mesothelioma
Beyond the preview
Go deeper on NCT07893340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07893340.